Medicare panel backs $93K cancer drug Provenge
Medicare advisers on Wednesday supported the effectiveness of the prostate cancer drug Provenge, an innovative therapy that has prompted questions about the cost of medical care and the government's role in paying for it.
The vote by a 14-member panel of outside experts amounts to a recommendation that Medicare pay for Provenge, which costs $93,000 per patient and extends life an average of four months.
- Technology Lights Up Health Innovation Forum
- NCQA Releases Annual Health Plan Rankings
- Few Winners Among MSSP Participants
- Data Points to Boom in Private HIX
- How much does that x-ray cost? You can find out in NH
- Interstate Medical Licensure Effort Advances
- Anthem Blue Cross, 7 CA Health Systems Create New Challenger, Business Model
- When a hospital closes
- Administration: 7.3M now enrolled in Obamacare
- US health system among least efficient before Obamacare